TABLE 01. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 02. PLASMA-DERIVED ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 03. PLASMA-DERIVED FACTOR VIII MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. PLASMA-DERIVED FACTOR IX MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. PLASMA-DERIVED IMMUNOGLOBULINS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. PLASMA-DERIVED HYPERIMMUNE GLOBULIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 07. OTHERS PLASMA DERIVED PRODUCTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 09. BLOOD PLASMA DERIVATIVES MARKET FOR HEMOPHILIA, BY REGION, 2016-2023 ($MILLION)
TABLE 10. BLOOD PLASMA DERIVATIVES MARKET FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2016-2023 ($MILLION)
TABLE 11. BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNODEFICIENCY DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 12. BLOOD PLASMA DERIVATIVES MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2016-2023 ($MILLION)
TABLE 13. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 15. BLOOD PLASMA DERIVATIVES MARKET FOR HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. BLOOD PLASMA DERIVATIVES MARKET FOR CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER END USERS, BY REGION, 2016-2023 ($MILLION)
TABLE 18. BLOOD PLASMA DERIVATIVES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 22. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 23. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 24. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 25. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 26. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 27. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 32. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 33. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 34. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 37. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 39. UK BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. UK BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. UK BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 42. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 43. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 45. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 46. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 48. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 51. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 52. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 53. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 55. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 56. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 57. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 58. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 59. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 61. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 62. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 64. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 65. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 66. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 67. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 68. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 69. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 76. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 77. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 78. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 79. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 80. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 81. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 82. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 83. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 86. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 89. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 90. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 91. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 92. BAXTER: COMPANY SNAPSHOT
TABLE 93. BAXTER: OPERATING SEGMENTS
TABLE 94. BAXTER: PRODUCT PORTFOLIO
TABLE 95. BIOTEST: COMPANY SNAPSHOT
TABLE 96. BIOTEST: OPERATING SEGMENTS
TABLE 97. BIOTEST: OPERATING SEGMENT
TABLE 98. CSL: COMPANY SNAPSHOT
TABLE 99. CSL: PRODUCT SEGMENTS
TABLE 100. CSL: PRODUCT PORTFOLIO
TABLE 101. FUSION HEALTHCARE: COMPANY SNAPSHOT
TABLE 102. FUSION HEALTHCARE: OPERATING DIVISION
TABLE 103. FUSION HEALTHCARE: PRODUCT PORTFOLIO
TABLE 104. GRIFOLS: COMPANY SNAPSHOT
TABLE 105. GRIFOLS: OPERATING SEGMENTS
TABLE 106. GRIFOLS: PRODUCT PORTFOLIO
TABLE 107. GREEN CROSS: COMPANY SNAPSHOT
TABLE 108. GREEN CROSS: OPERATING SEGMENTS
TABLE 109. GREEN CROSS: PRODUCT PORTFOLIO
TABLE 110. LFB: COMPANY SNAPSHOT
TABLE 111. LFB: PRODUCT SEGMENTS
TABLE 112. LFB: PRODUCT PORTFOLIO
TABLE 113. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 114. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 115. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 116. SHIRE: COMPANY SNAPSHOT
TABLE 117. SHIRE: PRODUCT PORTFOLIO
TABLE 118. SK CHEMICALS: COMPANY SNAPSHOT
TABLE 119. SK CHEMICALS: OPERATING SEGMENTS
TABLE 120. SK CHEMICALS: PRODUCT PORTFOLIO

LIST OF FIGURE

FIGURE 01. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06. TOP PLAYER POSITIONING, 2016
FIGURE 07. PERCENTAGE OF PEOPLE WITH HEMOPHILIA A IN THE U.S. IN 2016, BY AGE GROUP
FIGURE 08. IMPACT ANALYSES
FIGURE 09. COMPARATIVE ANALYSIS OF PLASMA-DERIVED ALBUMIN MARKET, 2016-2023 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF PLASMA-DERIVED FACTOR VIII MARKET, 2016-2023 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF PLASMA DERIVED FACTOR IX MARKET, 2016-2023 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF PLASMA-DERIVED IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF PLASMA DERIVED HYPERIMMUNE GLOBULIN MARKET, 2016-2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OTHERS PLASMA-DERIVED PRODUCTS MARKET, 2016-2023 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HEMOPHILIA MARKET, 2016-2023 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HYPOGAMMAGLOBULINEMIA MARKET, 2016-2023 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR IMMUNODEFICIENCY DISEASES MARKET, 2016-2023 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR VON WILLEBRAND DISEASE MARKET, 2016-2023 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATIONS, 2016-2023 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HOSPITALS MARKET, 2016-2023 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR CLINICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR OTHER END USER MARKET, 2016-2023 ($MILLION)
FIGURE 23. PERCENTAGE OF PEOPLE WITH HEMOPHILIA B IN THE U.S. IN 2016, BY AGE GROUP
FIGURE 24. AGE DISTRIBUTION OF THE UK POPULATION, 2006 TO 2046 (IN PERCENTAGE)
FIGURE 25. BAXTER: NET SALES, 2015-2017 ($MILLION)
FIGURE 26. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 27. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 28. BIOTEST: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. CSL: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. GRIFOLS: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. GRIFOLS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. GRIFOLS: REVENUE SHARE BY GEPGRAPHY, 2016 (%)
FIGURE 37. GREEN CROSS: NET SALES, 2014-2015 ($MILLION)
FIGURE 38. GREEN CROSS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. GREEN CROSS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. LFB: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 42. LFB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. OCTAPHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 44. SHIRE: NET SALES, 2015-2017 ($MILLION)
FIGURE 45. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 46. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. SK CHEMICALS: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. SK CHEMICALS: REVENUE SHARE BY SEGMENT, 2016 (%)